GSK wins European Anoro approval; Doc to get $18M in Botox case;

@FiercePharma: Pfizer's move on AstraZeneca outrages pols on two continents. More | Follow @FiercePharma

@TracyStaton: Popular at FiercePharmaMarketing: Payers fret about the next drug doomsday: Pricey PCSK9 cholesterol meds. Story | Follow @TracyStaton

@EricPFierce: CEO says Teva will close at least 11 plants, 15% of its network, and 16 more are being evaluated. Article | Follow @EricPFierce

@CarlyHFierce: U.K.'s NICE throws Astellas a bone on Xtandi--or does it? Report | Follow @CarlyHFierce

> The EU has greenlighted GlaxoSmithKline's ($GSK) new COPD treatment Anoro. Release

> Pennsylvania-based CSL Behring has opened a new manufacturing plant in Australia to make hemophilia therapies, part of a $250 million expansion there. Release

> Chicago area-based Akorn ($AKRX) says it has a $440 million deal to buy Marietta, GA-based VersaPharm. Report

> An Oklahoma City Ob/Gyn doctor is to get $18 from Allergan ($AGN) after winning the appeal of her case for contracting botulism in 2006 post-Botox injection. Release

Medical Device News

@FierceMedDev: Masimo hit with subpoena over patient-monitoring tech. More | Follow @FierceMedDev

@VarunSaxena2: House votes to make R&D tax credit permanent. What will Senate do? Seems to prefer 2 year extension. Story via WSJ (sub. req.) | Follow @VarunSaxena2

@MichaelGFierce: Double-locked virus needs two enzyme 'keys' to release drugs. Story via FierceDrugDelivery | Follow @MichaelGFierce

> Study finds common test of ICD patients to be unnecessary. More

> Counsyl raises $28M, launches BRCA test. Piece

Biotech News

@FierceBiotech: Chutes & Ladders: Brisol-Myers' senior VP of global development retires. Story | Follow @FierceBiotech

@JohnCFierce: Merck KGaA says for the umpteenth time they're going to do some pharma deals. Loaded for bear. More | Follow @JohnCFierce

@DamianFierce: Today in PfAy-Z: Pfizer cozies up to U.K. researchers in 5-year rare disease pact. Article | Follow @DamianFierce

@EmilyMFierce: Antibiotic-resistant genes are almost everywhere. News | Follow @EmilyMFierce

> Biotech's post-boom swoon mars IPO efforts from Radius, Agile. More

> Novartis-backed ImaginAb banks $21M for antibody tech. Article

> Merck wins FDA approval for a once-vaunted cardio drug. Report

And Finally... A poorly understood disease that affects the kidney has swept across Central America over the past decade, killing at least 20,000 and becoming the leading cause of deaths in hospitals among men in El Salvador. Story (sub. req.)

Suggested Articles

AZ's tremelimumab has so far suffered a host of clinical failures. But new trial results show the company might be able to use the drug in a new way.

Roche may have just grabbed the first FDA nod for a checkpoint med in previously untreated liver cancer, but Merck is hoping it won’t be far behind.

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.